Fastest Growing Stocks
LGND is part of our fastest growing stocks screen, indicating it has high EPS and sales growth.
LIGAND PHARMACEUTICALS (LGND) Stock Price & Overview
NASDAQ:LGND • US53220K5048
Current stock price
199.59 USD
-0.03 (-0.02%)
At close:
199.59 USD
0 (0%)
After Hours:
The current stock price of LGND is 199.59 USD. Today LGND is down by -0.02%. In the past month the price decreased by -3.24%. In the past year, price increased by 100.45%.
LGND Key Statistics
52-Week Range93.58 - 227.92
Current LGND stock price positioned within its 52-week range.
1-Month Range188.67 - 227.92
Current LGND stock price positioned within its 1-month range.
- Market Cap
- 3.98B
- P/E
- 24.82
- Fwd P/E
- 23.51
- EPS (TTM)
- 8.04
- Dividend Yield
- N/A
LGND Stock Performance
Today
-0.02%
1 Week
-2.02%
1 Month
-3.24%
3 Months
+4.99%
Longer-term
6 Months +10.28%
1 Year +100.45%
2 Years +185.58%
3 Years +161.42%
5 Years +36.81%
10 Years +65.13%
LGND Stock Chart
LGND Stock Screens
LGND currently appears in the following ChartMill screener lists.
Strong Buy Rated Stocks
LGND is part of our Strong Buy Rated Stocks screen, indicating it has a strong buy ratings from analysts and supporting business quality.
LGND Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to LGND. When comparing the yearly performance of all stocks, LGND is one of the better performing stocks in the market, outperforming 89.88% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
LGND Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to LGND. While LGND has a great profitability rating, there are some minor concerns on its financial health.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
LGND Earnings
On February 26, 2026 LGND reported an EPS of 2.02 and a revenue of 59.67M. The company beat EPS expectations (26.84% surprise) and beat revenue expectations (5.23% surprise).
Next Earnings DateMay 6, 2026
Last Earnings DateFeb 26, 2026
PeriodQ4 / 2025
EPS Reported$2.02
Revenue Reported59.666M
EPS Surprise 26.84%
Revenue Surprise 5.23%
LGND Forecast & Estimates
14 analysts have analysed LGND and the average price target is 250 USD. This implies a price increase of 25.26% is expected in the next year compared to the current price of 199.59.
For the next year, analysts expect an EPS growth of 5.61% and a revenue growth 10.22% for LGND
Analysts
Analysts85.71
Price Target250 (25.26%)
EPS Next Y5.61%
Revenue Next Year10.22%
LGND Groups
Sector & Classification
LGND Financial Highlights
Over the last trailing twelve months LGND reported a non-GAAP Earnings per Share(EPS) of 8.04. The EPS increased by 40.81% compared to the year before.
Income Statements
Revenue(TTM)268.09M
Net Income(TTM)124.45M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 46.42% | ||
| ROA | 7.97% | ||
| ROE | 12.23% | ||
| Debt/Equity | 0.44 |
Chartmill High Growth Momentum
EPS Q2Q%59.06%
Sales Q2Q%39.37%
EPS 1Y (TTM)40.81%
Revenue 1Y (TTM)60.4%
LGND Ownership
Ownership
Inst Owners106.63%
Shares19.94M
Float19.47M
Ins Owners1.81%
Short Float %7.49%
Short Ratio6.83
LGND Latest News, Press Relases and Analysis
2 days ago - By: Chartmill
LGND Competitors/Peers
The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 26.76 | 882.589B | ||
| JNJ | JOHNSON & JOHNSON | 20.87 | 585.389B | ||
| MRK | MERCK & CO. INC. | 23.36 | 298.838B | ||
| PFE | PFIZER INC | 9.48 | 161.094B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.41 | 121.374B | ||
| ZTS | ZOETIS INC | 16.66 | 49.786B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.4 | 28.018B | ||
| VTRS | VIATRIS INC | 5.36 | 15.475B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 21.94 | 11.475B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 8.619B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 6.372B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 5.599B | ||
| CORT | CORCEPT THERAPEUTICS INC | 51.43 | 4.52B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find more growth stocks the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About LGND
Company Profile
Ligand Pharmaceuticals, Inc. is a biopharmaceutical company that involves clinical development and commercialization of high-value medicines. The company is headquartered in Jupiter, Florida and currently employs 47 full-time employees. The company does this by financing, licensing its technologies or both. The company operates two infrastructure-light royalty-generating IP platform technologies. Its Captisol platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. This technology has enabled FDA-approved products, including Gilead’s Veklury, Amgen’s Kyprolis, Baxter’s Nexterone, and Acrotech Biopharma’s Evomela. Its NITRICIL platform technology facilitates tunable dosing, permitting an adjustable drug release profile to allow proprietary formulations that target a range of indications. Its technologies also include HepDirect, LTP and BEPro Technology Platform, and Pelican Expression Technology. The company has multiple alliances, licenses and other business relationships with various pharmaceutical companies.
Company Info
IPO: 1992-11-18
LIGAND PHARMACEUTICALS
555 Heritage Drive, Suite 200
Jupiter FLORIDA 92121 US
CEO: John L. Higgins
Employees: 47
Phone: 18585507500
LIGAND PHARMACEUTICALS / LGND FAQ
What does LIGAND PHARMACEUTICALS do?
Ligand Pharmaceuticals, Inc. is a biopharmaceutical company that involves clinical development and commercialization of high-value medicines. The company is headquartered in Jupiter, Florida and currently employs 47 full-time employees. The company does this by financing, licensing its technologies or both. The company operates two infrastructure-light royalty-generating IP platform technologies. Its Captisol platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. This technology has enabled FDA-approved products, including Gilead’s Veklury, Amgen’s Kyprolis, Baxter’s Nexterone, and Acrotech Biopharma’s Evomela. Its NITRICIL platform technology facilitates tunable dosing, permitting an adjustable drug release profile to allow proprietary formulations that target a range of indications. Its technologies also include HepDirect, LTP and BEPro Technology Platform, and Pelican Expression Technology. The company has multiple alliances, licenses and other business relationships with various pharmaceutical companies.
What is the current price of LGND stock?
The current stock price of LGND is 199.59 USD. The price decreased by -0.02% in the last trading session.
What is the dividend status of LIGAND PHARMACEUTICALS?
LGND does not pay a dividend.
What is the ChartMill technical and fundamental rating of LGND stock?
LGND has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
Which stock exchange lists LGND stock?
LGND stock is listed on the Nasdaq exchange.
What is LIGAND PHARMACEUTICALS worth?
LIGAND PHARMACEUTICALS (LGND) has a market capitalization of 3.98B USD. This makes LGND a Mid Cap stock.
Who owns LIGAND PHARMACEUTICALS?
You can find the ownership structure of LIGAND PHARMACEUTICALS (LGND) on the Ownership tab.